1. Home
  2. KRUS vs ACRS Comparison

KRUS vs ACRS Comparison

Compare KRUS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

N/A

Current Price

$34.96

Market Cap

485.4M

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.97

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRUS
ACRS
Founded
2008
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.4M
529.9M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
KRUS
ACRS
Price
$34.96
$3.97
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
★ $62.88
$10.09
AVG Volume (30 Days)
193.0K
★ 3.9M
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.75
69.01
EPS
N/A
★ N/A
Revenue
★ $282,763,000.00
$1,683,000.00
Revenue This Year
$16.80
N/A
Revenue Next Year
$17.77
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.88
N/A
52 Week Low
$29.69
$2.10
52 Week High
$80.84
$6.60

Technical Indicators

Market Signals
Indicator
KRUS
ACRS
Relative Strength Index (RSI) 42.00 45.37
Support Level $33.97 $3.18
Resistance Level $41.99 $4.67
Average True Range (ATR) 1.77 0.25
MACD -0.13 0.11
Stochastic Oscillator 47.71 86.34

Price Performance

Historical Comparison
KRUS
ACRS

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: